Union Pacific and Norfolk Southern Respond to STB’s Request for Supplemental Information, Submitting First Round of Their Responses

Union Pacific (UNP) and Norfolk Southern (NSC) filed the first portion of their responses to the STB’s May 28, 2026 request for additional information supporting their accepted merger application. The filing specifically addresses questions related to TRRA, KCT, and TTX Company, signaling continued regulatory process but providing no clear financial uplift or rejection risk in the news excerpt.

Analysis

This is a process signal more than a fundamental one: the market should read it as the deal moving into a slower, more political phase where every incremental disclosure tends to reduce the probability-weighted value of the synergies. The near-term effect is usually multiple compression on the acquirer and target because investors begin discounting longer closing timelines, more remedy risk, and a higher chance that the eventual approval comes with structural concessions that blunt the economics.

The key second-order issue is that the chokepoints being examined are exactly where regulators can force access terms, car/terminal sharing, or divestitures. That would protect incumbents like CSX and likely CPKC from a “too-powerful east-west rail” outcome, while keeping truck/intermodal alternatives such as JBHT and XPO from being competitively squeezed by a cleaner, faster network integration. If the merger stalls, the real winner is the status quo: both rails stay distracted, but the broader industry avoids a step-change in pricing power.

Consensus appears to be underestimating how long this can drag on versus how little actual P&L impact is visible before a final ruling. Over 1-3 months, the catalyst path is STB follow-up, shipper opposition, and remedy language; over 6-18 months, the issue becomes whether the companies can still extract any meaningful synergy after access concessions. The thesis is falsified if the STB signals a narrow, timetable-driven approval path with limited remedies, which would re-rate both stocks quickly.

Key Decisions for Investors

• Avoid chasing UNP/NSC on this filing; the risk/reward is poor until the STB’s remedy posture is clearer. Treat it as a watch item, not a catalyst to add risk.
• Pair trade: long CSX / short UNP for 1-3 months. CSX has less process risk and stands to benefit if regulatory friction keeps the combined east-west network from becoming a near-term competitive threat; target 5-8% relative outperformance.
• If you want event-risk exposure, use small-sized downside hedges on UNP or NSC rather than outright longs; a heavier-than-expected remedy package could take 5-10% off the names as synergy NPV gets marked down.
• For merger-arb accounts, wait for shipper comments and STB remedy language before initiating any spread exposure. The first meaningful re-pricing will likely come on regulatory tone, not on another routine filing.